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Abstract
We evaluated the impact of the OncotypeDX assay on adjuvant treatment decisions for Chinese patients with breast
cancer in Hong Kong. A comparison of pre-assay and post-assay recommendations demonstrated use of the infor-
mation for treatment recommendations, resulting in a 27% decrease in chemotherapy usage. In approximately 30%
of cases, physicians in the multidisciplinary committee agree/strongly agree that the assay inﬂuenced their decision.
Background: The Oncotype DX Breast Cancer Assay is validated to assess risk of distant recurrence and likelihood of
chemotherapy (CT) beneﬁt in estrogen receptor-positive ESBC in various populations. In HongKong,> 80%of breast cancers
are early stage breast cancer (ESBC) and> 60%of thesewomen receive CT. This prospective studymeasured changes in CT
type and recommendations, as well as physician impression of assay impact in a homogenous Chinese population.Methods:
Consecutive patients with estrogen receptor-positive, T1-3 N0-1mi M0 ESBC were offered enrollment. After surgery, physi-
cians discussed treatment options with patients, then ordered the assay, then reassessed treatment recommendation
considering assay results. Changes in treatment recommendation, CTutilization, physician conﬁdence, andphysician rating of
inﬂuence on their treatment recommendations were measured. Results: A total of 146 evaluable patients received pre- and
post-testing treatment recommendations. CT recommendations (including changes in intensity of CT) were changed for 34 of
146 patients (23.3%; 95% conﬁdence interval, 16.7%-31.0%); change in intensity occurred in 7 of 146 (4.8%). There were 27
changes in treatment recommendations of adding or removingCTaltogether (18.5%change; 95%conﬁdence interval, 12.6%-
25.8%).CT recommendationsdecreased from52.1%to37.7%,anet absolute reductionof 14.4%(P< .001; 27.6%net relative
reduction). Pre-assay, 96% of physicians agreed/strongly agreed that they were conﬁdent in their treatment recommendation;
post-assay, 90% of physicians agreed/strongly agreed with the same statement. Thirty percent of physicians agreed/strongly
agreed that the testhad inﬂuenced their recommendation,similar to theproportionofchangedrecommendations.Conclusions:
The Oncotype DX Assay appears to inﬂuence physician ESBC adjuvant treatment recommendations in Hong Kong.R.C
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Introduction overexpress HER2. Additional patient eligibility requirementsThe breast cancer burden in Asia represents one-third of the global
burden from this disease.1 Indeed, in Hong Kong, invasive breast
cancer is the most common cancer among women, with an incidence
of 91.7 per 100,000 in 2012.2 Of the cases of breast cancer in Hong
Kong, early stage breast cancer (ESBC, deﬁned as stages 0 to II) is the
most commonly diagnosed, accounting for > 80% of cases. Tumors
that are stage II, hormone receptor-positive, and HER2-negative
represent the largest proportion.3
Treatment decision-making for women with ESBC disease con-
tinues to be challenging. In Hong Kong, the majority of women with
breast cancer receive adjuvant therapy: 60.8% receive combination
chemotherapy (CT), and 66.7% receive hormonal therapy (HT)
following surgery.2,4 However, adjuvant CT yields only a small
reduction of risk of recurrence.5 Given that CT beneﬁts a small pro-
portion of ESBC patients, it would be ideal if CT could be targeted to
those women at highest risk of recurrence, sparing those women who
would not beneﬁt from adjuvant chemotherapy. Identifying these
women using traditional clinicopathologic criteria is imprecise.
The Oncotype DX Breast Cancer Assay has been validated to
assess the risk of distant recurrence and predict the likelihood of CT
beneﬁt in patients with estrogen receptor-positive (ERþ), HER2-
negative, lymph node-negative breast cancer. The Oncotype DX
test yields a Recurrence Score result between 0 and 100, which can
be used to categorize patients into low- (< 18), intermediate- (18-
30), and high-risk (> 30) groups. The prognostic and predictive
signiﬁcance of the test has been validated in several studies,6-13 and
its use is now incorporated into international breast cancer treat-
ment guidelines.14-18
Currently in Hong Kong, the decision to give adjuvant CT de-
pends on a combination of clinical, biologic, and pathologic factors,
which are often evaluated in the multidisciplinary committee (MDC)
setting. In this model, cases are reviewed by health care professionals
from several disciplines, including surgery, oncology, and pathology,
in an effort to optimize the treatment plan for each patient. An initial
retrospective, single-center assessment of the inﬂuence of genomic
technologies, such as the Oncotype DX Breast Cancer Assay, on the
decision to administer adjuvant therapy in a Chinese population
recently suggested the assay would help inform patient treatment
decisions.19 The purpose of this study was to extend those ﬁndings
through prospective evaluation of the inﬂuence of the assay onMDC
adjuvant treatment decisions atmultiple centers inHongKong and to
characterize the nature of that inﬂuence.Methods
Study Design
This single-arm prospective study was conducted at 6 institutions
in Hong Kong: Hong Kong Sanatorium and Hospital, Kwong Wah
Hospital Breast Center, United Christian Hospital Kowloon East
Cluster Breast Center, Pamela Youde Nether Sole Eastern Hospital,
St. Paul’s Hospital, and Northern District Hospital - New Terri-
tories Cluster Breast Center. Eligible physicians included oncolo-
gists and surgeons who represent the MDC in interactions with
patients with breast cancer (treating physicians). Eligible patients
included women between 18 and 69 years of age who have ESBC
(T1-2 N0 including N0(þi); T1pN1mic) that is ERþ and does notinclude Eastern Cooperative Oncology Group performance score of
0 or 1, and tumor sample adequate for Oncotype DX testing as
determined by central review at Genomic Health, Inc.
Following surgery and pathology assessment, participation was
offered to consecutive eligible patients at the ﬁrst post-surgery visit.
Consenting patients discussed their treatment plan with the treating
physician, and the cases were then presented at the MDC. The
MDC consensus treatment recommendations were used to com-
plete the pre-Oncotype DX treatment recommendation, then the
physician completed the remaining questionnaire items and the test
was ordered. Upon receipt of the test result, the case was reviewed
again by the MDC, and a second treatment recommendation was
made. At the second study visit, the treating physician reviewed the
post-assay treatment recommendation from the MDC with the
patient. The treating physician then completed the post-Oncotype
DX questionnaire, recording the revised MDC recommendation
and their responses to the additional questionnaire items.
The primary objective of this study was to characterize the effect
of the Oncotype DX Recurrence Score result on physicians’ treat-
ment recommendations, as informed by the MDC, by measuring
changes in these recommendations from before testing to after
testing. In addition, the changes in conﬁdence of the treating
physician in their treatment recommendation from before to after
testing were assessed.
Ethics Committees at each institution approved the study pro-
tocol. All subjects signed informed consent prior to enrollment in
the study.
Physician Questionnaires
The pre-assay questionnaire was answered by the treating
physician after the ﬁrst study visit. The questionnaire assessed the
pre-assay treatment recommendation from the MDC, as well as the
physician’s conﬁdence in the treatment decision. The intensity of
the CT regimen recommended (as deﬁned on the Adjuvant! Online
website20) was recorded. Examples of low-intensity regimens
included cyclophosphamide, methotrexate, and ﬂuorouracil (CMF),
doxorubicin and cyclophosphamide (AC), taxotere and cyclophos-
phamide (TC), or comparable regimens; examples of intermediate
intensity regimens included 5-ﬂuorouracil, doxorubicin, and
cyclophosphamide (FAC)/5-ﬂuorouracil, epirubicin, and cyclo-
phosphamide (FEC)  6, AC  4, and paclitaxel  4 in 3 weekly
cycles, or comparable regimens; examples of high-intensity regimens
included dose-dense AC then paclitaxel; docetaxel, doxorubicin, and
cyclophosphamide (TAC) or FEC/FAC  3 then docetaxel  3 or
comparable regimens. The post-assay questionnaire was completed
by the treating physician following a second MDC meeting and
second study visit. The revised treatment recommendation, the
physician’s conﬁdence in that recommendation after receiving
Oncotype DX information, and the inﬂuence of Oncotype DX in-
formation on the treatment decision were assessed.
Statistical Analyses
The study was designed with a planned enrollment of 150 patients.
The sample was described with descriptive statistics using the mean,
median, range, and 95% conﬁdence intervals (CIs) where appropriate.
The McNemar test was used to compare the proportion of patientsClinical Breast Cancer October 2016 - 373
Table 1 Patient and Tumor Characteristics
Characteristic n (%)
Number of Patients 146
Age
<40 years 11 (7.5)
40-49 years 47 (32.2)
50-59 years 51 (34.9)
60 years 37 (25.3)
Menopausal status
Pre 68 (46.6)
Post 78 (53.4)
Tumor size (cm)
1 23 (15.8)
1.1-2.0 77 (52.7)
2.1-4.0 44 (30.1)
>4.0 2 (1.4)
Tumor grade
1 37 (25.3)
2 69 (47.3)
3 36 (24.7)
N/A 4 (2.7)
T stage
1 30 (20.5)
1a 1 (0.7)
1b 19 (13.0)
1c 50 (34.2)
2 45 (30.8)
3 1 (0.7)
Nodal status
N0 123 (84.2)
ITC 10 (6.8)
N1(mi) 13 (8.9)
Estrogen receptor statusa
Positive 146 (100.0)
Negative 0 (0)
HER2b
Negative 72 (49.3)
Equivocal 74 (50.7)
Positive 0 (0)
Recurrence score
Low (<18) 74 (50.7)
Intermediate (18-30) 51 (34.9)
High (31) 21 (14.4)
aEstrogen receptor status determined by immunohistochemistry.
bHER2 status determined by immunohistochemistry; if equivocal (score of 2þ) patient retested
by ﬂuorescence in situ hybridization, with HER2/CEP17 ratio of 2.2 or greater indicating
positive.
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recommendation pre-Oncotype DX versus post-Oncotype DX. Phy-
sicians used a 5-category Likert scale to rate their level of agreement or
disagreement with pre- and post-assay statements for each patient. The
distribution of ratings (ie, proportions of patients with each rating)
were calculated for each statement. Pre- to post-assay changes in levels
of agreement/disagreement were analyzed.
Results
One hundred ﬁfty consecutive eligible patients at 6 centers were
enrolled. Of these, 4 patients were not evaluable: 2 had bilateral
tumors, 1 was estrogen receptor-negative by immunohistochem-
istry, and 1 was not recommended any adjuvant therapy. The 146
evaluable patients included 68 (46.6%) patients who were pre-
menopausal (Table 1). There were 123 patients (84.2%) who were
node-negative and 23 patients (15.8%) with micrometastatic dis-
ease. The patients had predominantly T1 tumors (100/146;
68.5%); 45 (30.8%) had T2 stage tumors. There was a single T3
stage tumor. Thirty-seven patients (25.3%) had low-grade tumors,
69 (47.3%) had intermediate-grade tumors, and 36 (24.7%) had
high-grade tumors; grade was not available for 4 patients (2.7%). All
146 patients (100.0%) had ERþ tumors (Allred score of 3 or
higher).
Just over half (74/146; 50.7%) of patients had low Recurrence
Score results (Table 1), while 51 patients (34.9%) had intermediate
Recurrence Score results, and 21 patients (14.4%) had results in the
high range. These results are similar to other published distributions
of Recurrence Score results.21-24
Any change in treatment recommendation, including changes in
the intensity of CT regimen, was examined in this study. We
observed an overall change in therapy recommendation in 34 of 146
patients (23.3%; 95% CI, 16.7%-31.0%; see Table 2), while a
change in CT intensity was observed in 7 of 146 patients (4.8%).
This represents a decrease in treatment intensity for 28 patients
(19.2%; 95% CI, 13.1%-26.5%) and an increase for 6 patients
(4.1%; 95% CI, 1.5%-8.7%). Changes in therapy recommendation
in which CT was either added or removed entirely after receiving
the Oncotype DX test results are shown in Table 3. Prior to
receiving the Oncotype DX result, 70 patients (47.9%) in this
cohort received an initial recommendation for HT alone, and 76
patients (52.1%) received a recommendation that included CT.
Following receipt of the assay results, 3 of the 70 patients (4.2%)
with a pre-assay recommendation for HT were recommended CHT
and 24 of the 76 patients (31.6%) with a pre-assay recommendation
for CHT were recommended HT. Therefore, adjuvant CT rec-
ommendations were changed for 27 of 146 patients (18.5%; 95%
CI, 12.6%-28.5%), and the proportion of patients receiving a
recommendation that included any kind of CT decreased from
52.1% pre-assay to 37.7% post-assay, for a net change of 14.4%
(P < .001; McNemar test) and a relative net change of 27.6%.
The impact of Recurrence Score results on the therapy recom-
mendation was also examined by Recurrence Score group (Table 2).
In the low Recurrence Score group, 21 (28.4%) patients had a
change in their therapy recommendation after receipt of the
Recurrence Score result. All changes were either to no CT (18
patients) or to lower intensity CT regimens (3 patients). Similarly,
in the intermediate Recurrence Score group, 7 (13.7%) patientsClinical Breast Cancer October 2016received a changed treatment recommendation: 6 patients for no
CT and 1 patient for lower intensity CT. In contrast, 6 (28.6%)
patients in the High Recurrence Score group received changed
treatment recommendations; 3 to add CT to HT and 3 to higher
intensity CT regimens.
Table 2 Changes in Treatment Recommendations
Recurrence Score Groups
Total n (%
of Group)
Low (<18)
n (% of
Group)
Intermediate
(18-30) n
(% of Group)
High (‡31)
n (% of
Group)
Any change 21 (28.4) 7 (13.7) 6 (28.6) 34 (23.3)
CHT to HT 18 (24.3) 6 (11.8) 0 (0) 24
Decrease
intensity of CHT
3 (4.1) 1 (2.0) 0 (0) 4
HT to CHT 0 (0) 0 (0) 3 (14.3) 3
Increase
intensity of CHT
0 (0) 0 (0) 3 (14.3) 3
Total 74 51 21 146
Abbreviations: CHT ¼ combined chemotherapy and hormone therapy; CT ¼ chemotherapy;
HT ¼ hormone therapy.
Roland C.Y. Leung et alPhysicians were queried about conﬁdence in their treatment
decisions before and after receipt of Oncotype DX information and
asked whether the test inﬂuenced their clinical decision. Before
receipt of the test results, 97 (66%) responded “agree” and 43
(29%) “strongly agree” to the statement, “I am conﬁdent in my
treatment recommendation prior to ordering Oncotype DX”
(Figure 1). After the test results were known, 74 (51%) responded
“agree” and 58 (40%) “strongly agree” with the statement, “I am
conﬁdent in my treatment recommendation after ordering the
Oncotype DX assay.” Responses regarding whether the Oncotype
DX assay result had inﬂuenced their treatment recommendation
were distributed similarly to the changes in treatment recommen-
dations: in 30% of the cases, physicians answered either “strongly
agree” or “agree” that the assay inﬂuenced their decision. Of the
remaining 70% of the cases, 57% responded “disagree” or “stronglyTable 3 Change in Chemotherapy Utilization
Post-Assay
HT
Alone
HT D
First-
Generation
CT
HT D
Second-
Generation
CT
HT D
Third-
Generation
CT All
Pre-assay
HT Alone 67 3 0 0 70
HT þ ﬁrst-
generation CTa
20 28 3 0 51
HT þ second-
generation CTb
4 4 15 0 23
HT þ third-
generation CTc
0 0 0 2 2
All 91 35 18 2 146
Abbreviations: CT ¼ chemotherapy; HT ¼ hormone therapy.
aFirst-generation chemotherapy regimens included cyclophosphamide, methotrexate, and
ﬂuorouracil (CMF), doxorubicin and cyclophosphamide (AC), taxotere and cyclophosphamide
(TC) or comparable regimens.
bSecond-generation chemotherapy regimens included 5-ﬂuorouracil, doxorubicin, and cyclo-
phosphamide (FAC)/5-ﬂuorouracil, epirubicin, and cyclophosphamide (FEC)  6, AC  4 and
paclitaxel  4 in 3 weekly cycles, or comparable regimens.
cThird generation chemotherapy regimens included dose-dense AC then paclitaxel; docetaxel,
doxorubicin, and cyclophosphamide (TAC) or FEC/FAC  3 then docetaxel  3, or comparable
regimens.disagree,” and 13% indicated “neither disagree nor agree” that the
test had inﬂuenced their decision. (Figure 2).
Discussion
Studies conducted in multiple countries support use of the
Oncotype DX Breast Cancer Assay as an independent prognostic
variable, in conjunction with conventional clinicopathologic pa-
rameters in predicting breast cancer recurrences.21-28 Use of this
assay has been incorporated into multiple clinical guidelines,
including the National Comprehensive Cancer Network, the
American Society of Clinical Onocology, the National Institute for
Health and Care Excellence, the European Society for Medical
Oncology, and the St Gallen Consensus as part of the adjuvant
therapy risk evaluation.14-18 This is the ﬁrst prospective study on
the impact of the Oncotype DX assay on adjuvant therapy decision-
making for Chinese patients and the ﬁrst to quantitate changes in
CT intensity resulting from Recurrence Score information.
We designed the study to evaluate the effect of the Recurrence
Score on the change in adjuvant therapy including changes in in-
tensity of chemotherapy, in addition to CT use or not. This was
included in order to gain insight into the real-world utility of the
assay. The decision to recommend adjuvant therapy for patients with
limited risk is a complex one that incorporates decisions not only on
whether to advise adjuvant therapy, but also the type of agent(s).
Increasing CT intensity (as deﬁned by the Adjuvant! Online clinical
risk calculator) confers greater risk reduction for recurrence of breast
cancer. Therefore, examining changes in CT intensity in relation to
Recurrence Score result may provide more granular insight into how
physicians integrate recurrence risk information into their CT
regimen decisions. The proportion of patients with a change in
treatment recommendation, including change in CT intensity, was
23%. Of these, 1 in 5 was a change in CT intensity, suggesting that
physicians found Recurrence Score information useful for ﬁner levels
of risk discrimination. The individual Recurrence Score results for
the down changes in CT intensity were 16, 16, 17, and 18, and the
scores for the increase in intensity were 43, 48, and 62. The down-
shifting of CT intensity occurred in patients with scores that fell
within the randomized group for the Trial Assigning IndividuaLized
Options for Treatment (TAILORx) trial. This may reﬂect a degree
of reservation to withhold CT completely in this group of patients at
present, pending the full results from the TAILORx trial. Although
there is no direct data showing that patients with very high scores
beneﬁt from increased intensity of CT, practitioners in this study
seemed to have adopted this view.
The decision change in adjuvant therapy looking at binary CT/
no CT recommendations from pre-assay to post-assay was 18.5%
which is slightly lower than the proportion of changes historically
observed.29 The predominant change observed was from CHT to
HT alone (14%). This is similar to the change reported for the N0
population by Eiermann et al (18% switch from CHT to HT). In
both of these studies, a high proportion (57% vs. 52% in this study)
of N0 patients received CT recommendations initially.27 The
apparently higher percentage of initial CT recommendations is best
explained by the perception by the physicians that these patients
have a higher risk of recurrence as deﬁned by clinical parameters
and, therefore, merit a more conservative initial therapy recom-
mendation in terms of avoiding undertreatment. Factors that mightClinical Breast Cancer October 2016 - 375
Figure 1 Physician Conﬁdence in Treatment Recommendation. Physicians Were Asked to Respond to the Statement, “I Am Conﬁdent
in My Treatment Recommendation Prior to Ordering Oncotype DX” by Selecting 1 of the 5 Responses on a 5-Point Likert
Scale. Following Receipt of the Recurrence Score Result, Physicians Were Asked to Respond to the Statement, “I Am
Conﬁdent in My Treatment Recommendation After Ordering the Oncotype DX Assay.” The Number of Responses in Each
Category Are Shown Above the Bar
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376 -drive the opinion that this cohort of patients is at a higher risk of
recurrence include the high proportion of premenopausal patients
(46.6%) and patients less than 50 years old (39.7%) in this study,
both of which are considered risk factors for recurrence. Analysis of
the much anticipated TAILORx study results, when they become
available, should clarify the use of Recurrence Score results in pa-
tients perceived as higher risk, as may be the case here.
This study also illustrates the effect of the Oncotype DX results
on the conﬁdence and perceptions of a cohort of physicians whoFigure 2 Physician Agreement on Inﬂuence of the Oncotype DX As
Respond to the Statement, “The Results of the Oncotype
Number of Responses in Each Category Are Shown Above
Clinical Breast Cancer October 2016historically had not had access to genomic classiﬁers. The high
conﬁdence in their treatment recommendations may reﬂect the
physicians’ comfort with basing recommendations on traditional
pathologic factors. Similar high levels of conﬁdence in recommen-
dations have been observed in other studies.21,25,30 Even with high
baseline conﬁdence, following receipt of the assay results, the pro-
portion of physicians who strongly agreed that they are conﬁdent in
their treatment recommendation further increased. When the
perception of inﬂuence of the assay results was measured, 30% ofsay on Treatment Recommendations. Physicians Were Asked to
DX Assay Inﬂuenced My Treatment Recommendations.” The
the Bar
Roland C.Y. Leung et alphysicians indicated that Oncotype DX had inﬂuenced their
treatment decision, which is commensurate with the overall rate of
decision changes observed. In fact, there was a statistically signiﬁ-
cant relationship between the answer to the inﬂuence question and a
change in treatment decision, with an afﬁrmative answer to the
inﬂuence question associated with a changed treatment recom-
mendation. This suggests that that the inﬂuence question was often
interpreted as indicating simply that the assay information was used
to change a treatment recommendation.
Although it is assumed that characteristics of breast cancer are similar
around the world, this study adds important information regarding the
biology of early breast cancer in women of Chinese descent. There are
data emerging from Taiwan that a higher proportion of young, pre-
menopausal patients with breast cancer reﬂects cancer population de-
mographics that are signiﬁcantly different from the Western world,
which may underlie the perception of higher recurrence risk in this
population.1,31,32 However, in this population of Chinese women, the
Recurrence Score distribution is similar to the distributions in studies
from other geographic areas. Therefore, additional studies of ESBC
patients from China may be needed to evaluate possible differences in
biology and any impact on the results of genomic classiﬁers.
In conclusion, this study demonstrates the value of adding the
Oncotype DX assay to the adjuvant treatment decision making
process for ERþ, node-negative ESBC and reduces CT usage in
Hong Kong. The impact of the assay on adjuvant therapy decision-
making is similar to, although somewhat lower than, other previous
international studies. Physician inexperience with the assay and
younger patient demographics may underlie this effect, which can
be further informed through additional studies.
Clinical Practice Points
 A minority of ESBC patients beneﬁt from adjuvant CT.
 Conventional risk stratiﬁcation tools do not accurately identify
those who can beneﬁt.
 In Western health care systems, the Oncotype DX assay has been
shown to accurately predict recurrence risk and reduce the uti-
lization of adjuvant CT.
 This study demonstrated that the Oncotype DX assay impacts
treatment decisions in an Asian health care system that utilizes the
multidisciplinary meeting model for treatment decision making.
 CT usage was reduced by 27%, and a similar proportion of
physicians reported that the assay results inﬂuenced their adju-
vant treatment recommendation.
 The study provides data on distribution of Recurrence Score
values in Hong Kong.
 This study is one of the ﬁrst to evaluate how the assay inﬂuences
choice of CT intensity.
 Use of the Oncotype DX assay may help reduce the frequency of
adjuvant CT usage and thereby reduce both CT-related
morbidity and associated costs.Acknowledgments
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